Travis Steed
Stock Analyst at B of A Securities
(2.85)
# 1,786
Out of 4,735 analysts
80
Total ratings
43.75%
Success rate
8.33%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $69.97 | +28.63% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $22.94 | +39.49% | 1 | Nov 5, 2024 | |
| SOLV Solventum | Maintains: Neutral | $70 → $60 | $74.02 | -18.94% | 2 | Jun 25, 2024 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $305 → $312 | $240.37 | +29.80% | 6 | May 6, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $31.48 | +42.95% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $32 → $3 | $0.81 | +271.79% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $395.85 | -20.42% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $276.08 | +6.85% | 3 | Aug 24, 2023 | |
| AXGN Axogen | Reiterates: Overweight | $16 | $18.97 | -15.66% | 5 | Aug 22, 2023 | |
| TNDM Tandem Diabetes Care | Downgrades: Underperform | $45 → $33 | $35.30 | -6.52% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $110.52 | +44.77% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $604.12 | -47.86% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $6.19 | +29.24% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $18.63 | +34.19% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 | $116.79 | +19.87% | 4 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $16.96 | +401.18% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $86.32 | +44.81% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $88.38 | +64.06% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $100.91 | -49.46% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $70.95 | +146.65% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $25.12 | +114.97% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $94.05 | -76.61% | 1 | Jul 17, 2017 |
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $69.97
Upside: +28.63%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $22.94
Upside: +39.49%
Solventum
Jun 25, 2024
Maintains: Neutral
Price Target: $70 → $60
Current: $74.02
Upside: -18.94%
Becton, Dickinson and Company
May 6, 2024
Maintains: Overweight
Price Target: $305 → $312
Current: $240.37
Upside: +29.80%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $31.48
Upside: +42.95%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $32 → $3
Current: $0.81
Upside: +271.79%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $395.85
Upside: -20.42%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $276.08
Upside: +6.85%
Axogen
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $18.97
Upside: -15.66%
Tandem Diabetes Care
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $35.30
Upside: -6.52%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $110.52
Upside: +44.77%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $604.12
Upside: -47.86%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $6.19
Upside: +29.24%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $18.63
Upside: +34.19%
May 31, 2022
Maintains: Buy
Price Target: $140
Current: $116.79
Upside: +19.87%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $16.96
Upside: +401.18%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $86.32
Upside: +44.81%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $88.38
Upside: +64.06%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $100.91
Upside: -49.46%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $70.95
Upside: +146.65%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $25.12
Upside: +114.97%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $94.05
Upside: -76.61%